
DNTH Stock Forecast & Price Target
DNTH Analyst Ratings
Bulls say
Dianthus Therapeutics Inc is well-positioned for growth, highlighted by the substantial expansion of the complement franchise in the broader market, which reached $6.5 billion in 2024, primarily driven by treatment-naive myasthenia gravis patients. The company’s lead candidate, DNTH103, is anticipated to demonstrate a favorable safety profile supported by positive Phase 2 data from riliprubart, suggesting strong clinical potential in managing autoimmune disorders. Moreover, with upcoming data readouts expected in the next 18 months and a growing enthusiasm among key opinion leaders for the company’s unique approach to monoclonal antibodies, Dianthus Therapeutics is set to enhance its competitive position in the biotechnology sector.
Bears say
Dianthus Therapeutics Inc. reported a substantial net loss of $28.4 million for the fourth quarter, translating to a loss of $0.81 per share, which may raise concerns about the company's financial sustainability given its high research and development expenses of $26.4 million. The reliance on external financing poses a significant risk, particularly if the company encounters delays or failures in its clinical trials, or if unexpected safety issues arise, potentially hindering the advancement of its therapeutic pipeline. Furthermore, the pressure of emerging competition and continued reliance on market capital raises additional uncertainties regarding the company's long-term viability in the biotech sector.
This aggregate rating is based on analysts' research of Magenta Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
DNTH Analyst Forecast & Price Prediction
Start investing in DNTH
Order type
Buy in
Order amount
Est. shares
0 shares